Symbiotec Pharmalab
Symbiotec Pharmalab, headquartered in India, is a prominent player in the pharmaceutical industry, specialising in the development and manufacturing of high-quality active pharmaceutical ingredients (APIs) and formulations. Founded in 1995, the company has established a strong presence in both domestic and international markets, with significant operational regions across Asia, Europe, and North America. With a commitment to innovation, Symbiotec Pharmalab offers a diverse range of products, including complex generics and niche therapeutic solutions, setting itself apart through rigorous quality standards and advanced manufacturing processes. The company has achieved notable milestones, including regulatory approvals from major global health authorities, reinforcing its market position as a trusted supplier in the pharmaceutical sector.
DitchCarbon Score
How does Symbiotec Pharmalab's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Symbiotec Pharmalab's score of 0 is lower than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Symbiotec Pharmalab's reported carbon emissions
In 2024, Symbiotec Pharmalab reported significant carbon emissions, with Scope 1 emissions totalling approximately 741,700 kg CO2e and Scope 2 emissions reaching about 32,704,000 kg CO2e. This marked an increase in emissions compared to previous years, where in 2023, Scope 1 emissions were about 516,000 kg CO2e and Scope 2 emissions were approximately 29,944,000 kg CO2e. In 2021, the company recorded Scope 1 emissions of about 13,872.64 kg CO2e and Scope 2 emissions of approximately 2,043.98 kg CO2e. The emissions data for 2022 is not available, but in 2020, Scope 1 emissions were about 14,285 kg CO2e and Scope 2 emissions were approximately 1,798.64 kg CO2e. Despite the increase in emissions in recent years, there are currently no disclosed reduction targets or climate pledges from Symbiotec Pharmalab. The company has reported specific CO2 emissions related to revenue, with figures of approximately 227,000 tonnes CO2e in 2021 and 210,000 tonnes CO2e in 2022. Overall, while Symbiotec Pharmalab has provided emissions data, it has yet to establish formal reduction initiatives or commitments to mitigate its carbon footprint.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2020 | 2021 | 2023 | 2024 | |
|---|---|---|---|---|
| Scope 1 | 14,285 | 00,000.00 | 000,000 | 000,000 |
| Scope 2 | 1,798.64 | 0,000.00 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Symbiotec Pharmalab is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
